The city of Deland, Florida, currently has 4 active clinical trials seeking participants for Atopic Dermatitis research studies.
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
NCT05277571
Recruiting
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2024
Locations: Up0110 103, DeLand, Florida
Conditions: Atopic Dermatitis
Register for Updates
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
NCT05372419
Recruiting
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/15/2024
Locations: Accel Research Sites, DeLand, Florida
Conditions: Atopic Dermatitis
Register for Updates
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
NCT05891119
Recruiting
The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/10/2024
Locations: Accel Research Sites (ACR), DeLand, Florida
Conditions: Atopic Dermatitis
Register for Updates
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
NCT05859724
Recruiting
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/09/2024
Locations: Annexus Dermatology & Aesthetics, DeLand, Florida
Conditions: Atopic Dermatitis
Register for Updates